1. DeLorenzo RJ, Hauser WA, Towne AR, et al.  A prospective, population based epidemiologic study of status epilepticus in Richmond, Virginia.  Neurology 1996;46:1029-35
2 Leppik IE, Derivan AT, Homan RW, et al. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983;249:1452-4.
3 Alldredge BK, Gelb AM, Isaacs M ea: A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus.  N Engl J Med 2001;345:631-637.
4 Lawn ND, Eijdicks EFM, Status Epilepticus: A critical review of management options. Can J Neurol Sci 2002;29:206-15.
5 Working Group on Status Epilepticus: Treatment of convulsive status epilepticus: Recommendations of the Epilepsy Foundations of America’s Working Group on Status Epilepticus. JAMA 1993;270:854-9.
6 Lowenstein DH, Bleck, T, Macdonald RL.  It’s time to revise the definition of status epilepticus.  Epilepsia,  1999; 40:120-122
7 Treiman DM, Meyers PD, Walton NY, et al. for the Veterans Affairs Status Epilepticus Cooperative Study Group.  A comparison of four treatments for generalized convulsive status epilepticus. NEJM 1998;339:792-8.
8 Coeytauz A, Jallon P, Galobardes B, et al.  Incidence of status epilepticus in French-speaking Switzerland (EPISTAR). Neurology 2000;55:693-7.
9 Knake S, Rosenow, F, Vescovi M, et al. Incidence if Status Epilepticus in Adults in Germany: A Prospective, Population-Based Study, Epilepsia 2001;42:714-8.
10 Vignatelli L, Caterina T, D’Alessandro R, Incidence and Short-term Prognosis of Status Epilepticus in Adults in Bologna, Italy,  Epilepsia 2003;44:964-68.
11 Logroscino G, Hesdorffer DC, Cascino GD, et al.  Long-term mortality after a first episode of status epilepticus. Neurology, 2002;58:537-41.
12 Lowenstein DH, Aldredge BK, Status Epilepticus, New Engl J Med 1998;338:970-6.
13 Jagoda A, Riggio S, Refractory status epilepticus in adults.  Ann Emerg Med, 1993;22:1337-48.
14 Walton NY, Treiman DM. Response of status epilepticus induced by lithium and pilocarpine to treatment with diazepam. Exo Neurol 7998;101:267-75.
15 Lowenstein DH, Aldredge BK. Status epilepticus in an urban hospital in the 1980s. Neurology 1993;43:483-8.
16 Meldrum B, Vigouroux R, Brierley J. Systemic factors and epileptic brain damage. Arch Neurol 1973; 29:82-87
17 The Collaborative Eclampsia Trial Group.  Which anticonvulsant for women with ecplampsia?  Evidence from the Collaborative Eclampsia Trial, Lancet, 1995; 345:1455-1463.
18 Aminoff M, Simon R. Status epilepticus: causes, clinical features and consequences in 98 patients. Am J Med 1980; 69:657-666.
19 Quigg M, Shneker B, Domer P.  Current practice in administration and clinical criteria of emergent EEG.  J Clin Neurophysiol, 2001;18:162-5.
20 Delorenzo RJ, Waterhouse EJ, Towne AR, et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998;39:833-40.
21 Alldredge BK, Gelb AM, Isaacs M ea: A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus.  N Engl J Med 2001;345:631-637.
22 Appleton RE, Sweeney A, Choonara I, Robson J, Molyneux E.  Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus.   Develpmental Medicine and Child Neurology 1995;37
23 Chamberlain JM, Altieri MA, Futterman C et al.. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care 1997;13:92-4.
24 Towne AR, DeLorenzo RJ.  Use of intramuscular midazolam for status epilepticus. J Emerg Med. 1999;17:323-8.
25 Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet 2003;42:33-58.
26 Browne T. The pharmacokinetics of agents used to treat status epilepticus. Neurology 1990;40:28-32.
27 Manno EM, New management strategies in the treatment of status epilepticus, Mayo Clin Proc. 2003;78:508-18.
28 Kilarski DJ, Buchanan C, Von Behren L. Soft-tissue damage associated with intravenous phenytoin.  N Engl J Med 1984;3111:1186-7.
29 O’Brien TJ, Cascino GD, So EL, Hanna DR.  Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin therapy.  Neurology 1998;51:1034-9.
30 Burneo JG, Anandan JV, Brakley GL.  A prospective study of the incidence of the purple glove syndrome.  Epilepsia 2001;42:1156-9.
31 Rosenow F, Arzimanoglou A, et al.  R2.ecent developments in treatment of status epilepticus: A review.  Epileptic Disorders 2002;4(2 Suppl 2): S41-S51.
32 Browne TR, Kugler AR, Eldon MA.  Pharmacology and pharmacokinetics of fosphenytoin.  Neurology 1996;46(6 Suppl 1):S3-S7.
33 Devinsky O, Leppik I, Willmore LJ, et al.  Safety of intravenous valproate.   Ann Neurol. 1995;38:670-4.
34 Giroud M, Gras D, Escousse A, Dumas R, Venaud G. Use of injectable valproic acid in status epilepticus.  Drug Investigation 1993;5:154-159.
35 Hovinga CA, Chicella MF, Rose DF, Eades SK, Dalton JT, Phelps SJ. Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus.  Ann Pharmacother. 1999;33:579-584
36 Venkataraman V, Wheless JW.  Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res 1999;35:147-153.
37Giroud M, Grass D, Ecousse A, et al. Use of injectable valproic acid in status epilepticus: a pilot study.   Drug Invest 1993;5:154-9.
38 Shaner DM, McCurdy SA, Herring MO, Gabor AJ. Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin, Neurology 1988;38:202-7.
39 Treiman DM, Meyers PD, Walton NY, et al. for the Veterans Affairs Status Epilepticus Cooperative Study Group.  A comparison of four treatments for generalized convulsive status epilepticus. NEJM 1998;339:792-8.
40 Walker L, Slovis C. Lidocaine in the treatment of status epilepticus. Acad Emerg Med 1997; 4:918-922
41 Pascual J, Sedano M, Polo J. Intravenous lidocaine for status epilepticus. Epilepsia 1988; 29:584-589.
42 Lampl Y, Eshel Y, Gilad R, et al. Chloral hydrate in intractable status epilepticus. Ann Emerg Med 1990; 19:674-676.
43 Yeoman P, Hutchinson A, Byrne A, et al. Etomidate infusions for the control of refractory status epilepticus. Intensive Care Med 1989; 15:255-259.
44 Kumar A, Bleck TP.  Intravenous midazolam for the treatment of refractory status epilepticus.  Crit Care Med 1992;20:483-8.
45 Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review.  Epilepsia 2002; 43: 146-153.
46 Praasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of Refractory Status Epilepticus. Epilepsia, 2001;42:380-6.
47 Brown LA, Levin GM. Role of propofol in refractory status epilepticus.  Annals of Pharmacotherapy, 1998;32:1053-59.
48 Cannon ML, Glazier SS, Bauman LA.  Metabolic acidosis, rhabdomyolysis, and cardiovascular collapse after prolonged propofol infusion.  J Neurosurg 2001;95:1053-56.
49 Bray RJ. Propofol infusion syndrome  in children.  Paediatr Anaesth 1998;8:491-9.
50 Makela JP, Livanainen M, Pieninkeroinen IP. Seizures associated with propofol anesthesia. Epilepsia 1993;34:832-5.
51 Parviainen I, Uusaro a, Kalviainen R, et at. High-dose thiopental in the treatment of refractory status epilepticus in the intensive care unit. Neurology, 2002;59:1249-51.
52 Manno EM, New management strategies in the treatment of status epilepticus, Mayo Clin Proc. 2003;78:508-18.